LY-301317

LY-301317
Clinical data
Other names	LY301317; (R)-4,α-Methylene-5-(1,3-oxazol-5-yl)-N,N-dipropyltryptamine; (R)-4,α-Methylene-5-(1,3-oxazol-5-yl)-DPT
Drug class	Serotonin 5-HT1A receptor agonist; Simplified/partial LSD analogue
ATC code	None;
Identifiers
	IUPAC name (4R)-6-(1,3-oxazol-5-yl)-N,N-dipropyl-1,3,4,5-tetrahydrobenzo[cd]indol-4-amine;
PubChem CID	9949130;
ChemSpider	8124741;
Chemical and physical data
Formula	C20H25N3O
Molar mass	323.440 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN(CCC)[C@H]1CC2=CNC3=C2C(=C(C=C3)C4=CN=CO4)C1;
	InChI InChI=1S/C20H25N3O/c1-3-7-23(8-4-2)15-9-14-11-22-18-6-5-16(17(10-15)20(14)18)19-12-21-13-24-19/h5-6,11-13,15,22H,3-4,7-10H2,1-2H3/t15-/m0/s1; Key:WVWRMVCFJMZWKO-HNNXBMFYSA-N;

LY-301317, also known as (R)-4,α-methylene-5-(1,3-oxazol-5-yl)-N,N-dipropyltryptamine ((R)-4,α-methylene-5-(1,3-oxazol-5-yl)-DPT), is a potent and selective serotonin 5-HT_1A receptor agonist which has been used in scientific research.^[1]^[2] It is a cyclized tryptamine and a partial ergoline.^[2] The drug shows very high affinity for the serotonin 5-HT_1A receptor, with a K_i of 0.26 nM, and is highly selective for this receptor over 9 other assessed targets.^[1]^[2] It produces various serotonin 5-HT_1A receptor agonist-associated effects in animals, including behavioral effects, hypothermia, antidepressant-like, anxiolytic-like, and antiemetic effects, and discriminative stimulus effects in drug discrimination tests.^[1]^[2]^[3]^[4] LY-301317 was first described in the scientific literature in 1996.^[5]^[2]